Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation

American Journal of Hematology

Volumn 52, Issue 3, 1996, Pages 165-170

  Shimura, Minori ^a   Wada, Hideo ^a   Wakita, Yoshihiro ^a   Nakase, Tutomu ^a   Hiyoyama, Katsuyo ^a   Nagaya, Shozaburo ^a   Mori, Yositaka ^b   Shiku, Hiroshi ^a  

^a MIE UNIVERSITY   (Japan)

^b Mie Red Cross Blood Center   (Japan)

Author keywords

DIC; Outcome; TF; TF TFPI ratio; TFPI

Indexed keywords

THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ARTICLE; BLOOD LEVEL; CANCER PATIENT; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; HUMAN; HUMAN CELL; LEUKEMIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIUM;

ANTICOAGULANTS; DISSEMINATED INTRAVASCULAR COAGULATION; HUMANS; LIPOPROTEINS; REFERENCE VALUES; THROMBOPLASTIN; TREATMENT OUTCOME;

EID: 0029680606     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(199607)52:3<165::AID-AJH5>3.0.CO;2-R     Document Type: Article

References (29)

1. Nemerson Y, Bach R: Tissue factor revisited. Prog Hemostasis 6:237-261, 1982.
2. Nemerson Y: Tissue factor and hemostasis. Blood 71:1-8, 1988.
3. Weiss HJ, Lages B: Evidence for tissue factor-dependent activation of the classic extrinsic coagulation mechanism in blood obtained from bleeding time wounds. Blood 71:629-635, 1988.
4. Rodgers GM: Hemostatic properties of normal and perturbed vascular cells. FASEB J 1:116-123, 1988.
5. Rapaport SI: The extrinsic pathway inhibitor: A regulation of tissue type factor-dependent blood coagulation. Thromb Haemost 66:6-15, 1991.
6. Broze GJ, Warren LA, Novotny WF, Higuchi DA, Girard TJ, Miletich JG: The lipoprotein-associated coagulation inhibitor that inhibits factor VII-tissue factor complex also inhibits Xa: Insight into its possible mechanism of action. Blood 71:335-343, 1988.
7. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ: Cloning and characterization of a cDNA coding for the lipoprotein associated coagulation inhibitor shows that it consists of three tandem Kunitz type inhibitory domains. J Biol Chem 263:6001-6004, 1988.
8. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Meletich JP, Broze GJ: Functional significance of the Kunitz type inhibitory domains of lipoprotein associated coagulation inhibitor. Nature 338:518-520, 1989.
9. Bick RL: Disseminated intravascular coagulation and related syndromes: A clinical review. Semi Thromb Hemost 14:299-338, 1988.
10. Muller-Berghaus G: Pathophisiologic and biochemical events in disseminated intravascular coagulation: Dysregulation of procoagulant and anticoagulant pathways. Semi Thromb Hemost 15:58-98, 1989.
11. Wada H, Ohiwa M, Kaneko T, Tamaki S, Tanigawa M, Shirakawa S, Koyama M, Hayashi T, Suzuki K: Plasma thrombomoculin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation. Am J Hematol 39:20-24, 1992.
12. Wada H, Minamikawa K, Wakita Y, Nakase T, Ohiwa M, Tamaki S, Deguchi K, Shirakawa S, Hayashi T, Suzuki K: Increased vascular endothelial cell markers in patients with disseminated intravascular coagulation. Am H Hematol 44:85-88, 1993.
13. Weissbach G, Herenberg J, Wendisch J, Pargec N, Thomas K: Tissue factor pathway inhibitor in infants and children. Thromb Res 73:441-446, 1994.
14. Brandtzaeg P, Sandset PM, Joo HB, Ovstevo R, Abildgarrd U, Kierulf P: The quantitative association of plasma endotoxin, antithrombin. protein C, extrinsic pathway inhibitor and fibrinopeptide a in systemic meningcoccal disease. Thromb Res 55:459-470, 1989.
15. Kobayashi N, Maegawa T, Takada M, Tanaka H, Gonmori H: Criteria for diagnosis of DIG based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol 49:265-275, 1987.
16. Wada H, Minamikawa K, Wakita Y, Nakase T, Ohiwa M, Tamaki S, Deguchi A, Mori Y, Deguchi K, Shirakawa S, Suzuki K: Hemostatic study before onset of disseminated intravascular coagulation. Am J Hematol 43:190-194, 1994.
17. Ohno H, Kosaki G, Kambayashi J, Imaoka S, Hirata F: FOY; [ethyl p-(6-guanidinohexanoxyloxy) benzoate] methaneslfonate as a serine protease inhibitor. I. Inhibition of thrombin and factor Xa in vitro. Thromb Res 19:579-588, 1980.
18. Ohno H, Kambayashi J, Chang SW, Kosaki G: FOY; [ethyl p-(6-guanidinohexanoxyloxy) benzoate] methaneslfonate as a serine protease inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with haparin or aprotinin. Thromb Res 24:445-452, 1981.
19. Morrissey JH, Fair DS, Edgington TS: Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 52:247-261, 1988.
20. Wada H, Nakase T, Nakaya R, Minamikawa K, Wakita Y, Kaneko T, Ohiwa M, Deguchi K, Shirakawa S: Elevated plasma tissue factor antigen level in patients with disseminated intravascular coagulation. Am J Hematol 45:232-236, 1994.
21. Kobayashi M, Wada H, Wakita Y, Shimura M, Nakase T, Hiyoyama K, Nagaya S, Minami N, Nakano T, Shiku H: Decreased plasma tissue factor pathway inhibitor levels in patients with thrombotic thromocytopenic purpura. Thromb Hemost 73:10-14.
22. Gralnick HR, Abrell E: Studies on the procoagulant and fibrinolytic activity of promyelocytic leukemia. Br J Haematol 24:89-98, 1973.
23. Wada H, Nagano T, Tomeoku M, Kuto M, Karitani Y, Deguchi K, Shirakawa S: Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res 30:315-322, 1982.
24. Charsen E, Flatmark A, Prydz H: Cytokine-induced procoagulant activity in monocytes and endothelial cells. Transplantation 46:575-580, 1988.
25. Wada H, Tanigawa M, Wakita Y, Nakase T, Minamikawa K, Kaneko T, Ohiwa M, Kageyama S, Kobayashi T, Noguchi T, Deguchi K, Shirakwa S: Increased plasma level of interleukin-6 in disseminated intravascular coagulation. Blood Coag Fibr 4:583-590, 1993.
26. Warr TA, Rao LVM, Rapaport SI: Human plasma extrinsic pathway inhibitor activity; II plasma levels in disseminated intravascular coagulation and hepatocellular disease. Blood 74:994-998, 1989.
27. Sandset PM, Hogevold HE, Lyberg T, Andersson TR, Abildgarrd U: Extrinsic pathway inhibitor in elective surgery; A comparison with other coagulation inhibitors. Thromb Haemost 62:856-860, 1989.
28. Novotny WF, Palmier M, Wun T-C, Broze GJ, Miletich JP: Purfication and properties of heparin-releasable lipoprotein-associated coagulation inhibitor. Blood 78:394-400, 1991.
29. Warshawsky I, Bu G, Mast A, Saffitz JE, Broze Jr GJ, Schwanz AL: The carboxy terminus of tissue factor pathway inhibitor is required for interacting with hepatoma cells in vitro and in vivo. J Clin Invest 95:1773-1781, 1995.